BR9814951A - Derivado de ácido carboxìlico, uso do mesmo, preparação de medicamento para o uso oral, parenteral, combinação, uso de compostos, fragmento estrutural, uso do mesmo, antagonista de receptor de endotelina, e, composto - Google Patents

Derivado de ácido carboxìlico, uso do mesmo, preparação de medicamento para o uso oral, parenteral, combinação, uso de compostos, fragmento estrutural, uso do mesmo, antagonista de receptor de endotelina, e, composto

Info

Publication number
BR9814951A
BR9814951A BR9814951-2A BR9814951A BR9814951A BR 9814951 A BR9814951 A BR 9814951A BR 9814951 A BR9814951 A BR 9814951A BR 9814951 A BR9814951 A BR 9814951A
Authority
BR
Brazil
Prior art keywords
carboxylic acid
oral
compounds
compound
preparation
Prior art date
Application number
BR9814951-2A
Other languages
English (en)
Inventor
Wilhelm Amberg
Rolf Jansen
Stefan Hergenroeder
Manfred Raschack
Liliane Unger
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19752904A external-priority patent/DE19752904A1/de
Priority claimed from DE1998109376 external-priority patent/DE19809376A1/de
Application filed by Basf Ag filed Critical Basf Ag
Publication of BR9814951A publication Critical patent/BR9814951A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

"DERIVADO DE áCIDO CARBOXìLICO, USO DO MESMO, PREPARAçãO DE MEDICAMENTO PARA O USO ORAL, PARENTERAL, COMBINAçãO, USO DE COMPOSTOS, FRAGMENTO ESTRUTURAL, USO DO MESMO, ANTAGONISTA DE RECEPTOR DE ENDOTELINA, E, COMPOSTO". A invenção diz respeito a derivados de ácido carboxílico da fórmula (I) em que os substituintes têm os significados como comentados na descrição. Também diz respeito à produção e ao uso dos mesmos como antagonistas do receptor de endotelina.
BR9814951-2A 1997-10-31 1998-10-16 Derivado de ácido carboxìlico, uso do mesmo, preparação de medicamento para o uso oral, parenteral, combinação, uso de compostos, fragmento estrutural, uso do mesmo, antagonista de receptor de endotelina, e, composto BR9814951A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19748238 1997-10-31
DE19752904A DE19752904A1 (de) 1997-10-31 1997-11-28 Neue Carbonsäurederivate, die Amidseitenketten tragen, ihre Herstellung und Verwendung als Endothelin-Rezeptorantagonisten
DE1998109376 DE19809376A1 (de) 1998-03-05 1998-03-05 Neue Carbonsäurederivate, die Amidseitenketten tragen, ihre Herstellung und Verwendung als Endothelin-Rezeptorantagonisten
PCT/EP1998/006571 WO1999023078A2 (de) 1997-10-31 1998-10-16 Neue carbonsäurederivate, die amidseitenketten tragen, ihre herstellung und verwendung als endothelin-rezeptorantagonisten

Publications (1)

Publication Number Publication Date
BR9814951A true BR9814951A (pt) 2000-10-03

Family

ID=27217881

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9814951-2A BR9814951A (pt) 1997-10-31 1998-10-16 Derivado de ácido carboxìlico, uso do mesmo, preparação de medicamento para o uso oral, parenteral, combinação, uso de compostos, fragmento estrutural, uso do mesmo, antagonista de receptor de endotelina, e, composto

Country Status (18)

Country Link
US (1) US6509341B1 (pt)
EP (1) EP1027338A2 (pt)
JP (1) JP2001521927A (pt)
CN (1) CN1278251A (pt)
AU (1) AU2266199A (pt)
BG (1) BG104396A (pt)
BR (1) BR9814951A (pt)
CA (1) CA2307770A1 (pt)
HR (1) HRP980560A2 (pt)
HU (1) HUP0100054A3 (pt)
ID (1) ID24278A (pt)
IL (1) IL135347A0 (pt)
NO (1) NO20002124D0 (pt)
NZ (1) NZ504316A (pt)
PL (1) PL340871A1 (pt)
SK (1) SK4592000A3 (pt)
TR (1) TR200001182T2 (pt)
WO (1) WO1999023078A2 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19806438A1 (de) * 1998-02-17 1999-08-19 Basf Ag Neue Carbonsäurederivate mit 5-substituiertem Pyrimidinring, ihre Herstellung und Verwendung
DE19933164A1 (de) * 1999-07-20 2001-01-25 Basf Ag Neue Carbonsäurederivate mit 5,6 substituiertem Pyrimidinring, ihre Herstellung und Verwendung als Endothelin Rezeptorantagonisten
AU779266B2 (en) 2000-05-11 2005-01-13 Banyu Pharmaceutical Co., Ltd. N-acyltetrahydroisoquinoline derivatives
DE10025728A1 (de) * 2000-05-25 2001-11-29 Basf Ag Neue Carbamate und Harnstoffe, ihre Herstellung und Verwendung als Endothelin-Rezeptorantagonisten
WO2002064573A1 (de) * 2001-02-14 2002-08-22 Abbott Gmbh & Co. Kg Neue carbonsäurederivate mit alkylsubstituierten triazinen, ihre herstellung und verwendung als endothelin-rezeptorantagonisten
ES2262567T3 (es) 2001-03-20 2006-12-01 Schwarz Pharma Ag Nuevo uso de una clase peptidica de compuesto para tratamiento del dolor inflamatorio no neuropatico.
DK1243263T3 (da) 2001-03-21 2003-03-17 Sanol Arznei Schwarz Gmbh Hidtil ukendt anvendelse af en klasse af peptidforbindelser til behandling af allodyni eller andre forskellige typer af kronisk- eller fantomsmerte
EA013591B1 (ru) 2004-04-16 2010-06-30 Шварц Фарма Аг Применение пептидных соединений для профилактики, облегчения и лечения головной боли и болезненных состояний, связанных с или вызванных распространяющейся кортикальной депрессией (csd)
EP1604656A1 (en) 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS)
EP1781276B1 (en) 2004-08-27 2010-06-23 UCB Pharma GmbH Use of peptide compounds for treating bone cancer pain, chemotherapy- and nucleoside-induced pain
BRPI0709950A2 (pt) * 2006-04-13 2011-08-02 Actelion Pharmaceuticals Ltd uso de bosentan na preparação de um medicamento para o tratamento de fibrose pulmonar idiopática em estágio precoce e uso de antagonista do receptor endotelin
AR061476A1 (es) 2006-06-15 2008-08-27 Sanol Arznei Schwarz Gmbh Composicion farmaceutica con efecto anticonvulsivo sinergico

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4313412A1 (de) 1993-04-23 1994-10-27 Basf Ag 3-(Het)aryl-Carbonsäurederivate, Verfahren und Zwischenprodukte zu ihrer Herstellung
DE4313413A1 (de) * 1993-04-23 1994-10-27 Basf Ag 3-(Het)aryloxy(thio)-Carbonsäurederivate, Verfahren und Zwischenprodukte zu ihrer Herstellung
DE4411225A1 (de) 1994-03-31 1995-10-05 Basf Ag Verwendung von Carbonsäurederivaten als Arzneimittel
DE19533023B4 (de) * 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
DE19614534A1 (de) * 1996-04-12 1997-10-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung

Also Published As

Publication number Publication date
WO1999023078A2 (de) 1999-05-14
HRP980560A2 (en) 1999-08-31
BG104396A (en) 2001-02-28
IL135347A0 (en) 2001-05-20
EP1027338A2 (de) 2000-08-16
AU2266199A (en) 1999-05-24
NO20002124L (no) 2000-04-26
JP2001521927A (ja) 2001-11-13
SK4592000A3 (en) 2000-12-11
NZ504316A (en) 2002-12-20
HUP0100054A3 (en) 2002-03-28
TR200001182T2 (tr) 2000-11-21
CN1278251A (zh) 2000-12-27
WO1999023078A3 (de) 1999-09-10
US6509341B1 (en) 2003-01-21
ID24278A (id) 2000-07-13
NO20002124D0 (no) 2000-04-26
PL340871A1 (en) 2001-03-12
CA2307770A1 (en) 1999-05-14
HUP0100054A1 (hu) 2002-02-28

Similar Documents

Publication Publication Date Title
BRPI0215312B8 (pt) composto, uso de um composto, composição farmacêutica, e processo para a preparação de um composto
BRPI0519398A2 (pt) compostos de piridina para o tratamento de doenÇas mediadas por prostaglandina
BR0010215A (pt) Derivados de indolina como antagonistas de progesterona
BR9915403A (pt) Antagonistas receptores iii de 4-aroil-piperidin-ccr-3
BR0017030B8 (pt) derivados de tiazolilamida, processo para sua preparação, composição farmacêutica que os compreende e uso dos mesmos
CY1108101T1 (el) Ενωσεις πυριμιδινης και η χρηση τους στην παρασκευη ενος τριαζολο-πυριμιδιν καρβα νουκλεοζιτη
BR9910583A (pt) Aminotetralinas n-substituìdas como ligantes para o receptor de neuropeptìdeo y y5 úteis no tratamento de obesidade e outros distúrbios
BR9814951A (pt) Derivado de ácido carboxìlico, uso do mesmo, preparação de medicamento para o uso oral, parenteral, combinação, uso de compostos, fragmento estrutural, uso do mesmo, antagonista de receptor de endotelina, e, composto
BR9712816A (pt) Derivados de benzamidina e seu uso como medicamentos com uma atividade antagonista ltb4
BR0109814A (pt) Derivados de indolin-2-ona e sua utilização como ligantes dos receptores da ocitocina
NO985518D0 (no) Morfinanderivater og medisinsk anvendelse derav
BR0013311A (pt) Derivados substituìdos de 1,5-dihidropirrol-2-ona eficazes como antagonistas de receptores nmda para o tratamento de estados de dor
BR9910144A (pt) Antagonistas de receptores de quimiocinas e seu uso
BR9811093A (pt) Piridinas substituìdas com 2-amino-6-(4-fenóxi 2-substituìdo)
AR025052A1 (es) Derivados de 2-dialquilaminoalquilbifenilo sustituidos, procedimiento para su preparacion, medicamentos que contienen estos compuestos y el uso de estoscompuestos para la preparacion de medicamentos.
BRPI0418255A (pt) derivados de piperazina e piperidina n-substituìdos
CR6398A (es) Antagonistas de 5ht1 para terapia antidepresiva
BR0114380A (pt) Derivados-1-aminobutan-3-ol-substituìdos
BR0013313A (pt) Derivados substituìdos de pirrolidino-2,3,4- triona-3-oxina eficazes como antagonistas de receptores de nmda
BRPI0417946A (pt) composto, métodos para o tratamento ou a profilaxia de uma doença ou condição, e de distúrbios, e para a indução da cessação do hábito de fumar, composição farmacêutica, e, uso de um composto
BR9810182A (pt) Derivado de ácido ß-amino e ß-azido carboxìlico, uso do mesmo, formulação de medicamento para administração oral, parenteral ou intraparenteral, composto,uso do mesmo, e, fragmento estrutural
BR9705456A (pt) Compostos heterocìclicos, processo de aminometila para sua preparação e composições farmacêuticas que os contêm.
BR9714047A (pt) Derivados de ácido carboxìlico, uso dos mesmos, combinação destes com um ou mais compostos ativos, preparação de drogas para a administração oral e parenteral, e, antagonista de receptor de endotelina
BR9805437A (pt) Derivados de benzocicloalquenos heterocìclicos, processo para fabricação de derivados de benzocicloalquenos heterocìclicos e uso de derivados de benzocicloalquenos heterocìclicos.
BR0010092A (pt) Composto, preparação farmacêutica para a administração oral ou parenteral, uso de um composto, e, uso da preparação farmacêutica

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Free format text: ABBOTT GMBH & CO. KG (DE)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5O, 6O, 7O, 8O E 9O ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1910 DE 14/08/2007.